Showing 51–75 of 200 documents
Sorted by hybrid relevance (keyword + semantic via RRF)
Hassane-Harouna S, Cherif GF, Ortuno-Gutierrez N, Cisse D, Camara LM, et al.
Setting Since August 2016, after the Ebola outbreak, the Guinean National Tuberculosis Programme and Damien Foundation implemented the shorter treatment regimen (STR) for multidrug-resistant tuberculosis (MDR-TB) in the three MDR-TB sites of Conakry. Previously, the longer regime…
Bern-Thomas Nyang'wa, MD
… controlled, phase II-III trial; evaluating short treatment regimens containing bedaquiline and pretomanid in combination with existing and re-purposed anti-TB drugs for the treatment of biologically confirmed pulmonary multi drug-resistant TB (MDR-TB). This is a multi-centre, o…
Mbelele PM, Mbelele PM, Mpolya EA, Sauli E, Mtafya B, et al.
…erculosis (RR/MDR-TB) treatment has largely transitioned to regimens free of the injectable aminoglycoside component, despite the drug class' purported bactericidal activity early in treatment. We tested whether Mycobacterium tuberculosis killing rates measured by tuberculosis mo…
Ajay Gupta
…torically required long, toxic, and operationally demanding regimens–often extending beyond 18 months and associated with treatment fatigue, high default rates, and severe adverse effects. Against this background, the World Health Organization recommended the all-oral, 6-month BP…
Rivaldo Heru Setiawan
…) contributing substantially to poor outcomes. Conventional regimens span 18–24 months, leading to limited adherence and treatment success. Shorter treatment regimens (STRs), such as the BPaL regimen (bedaquiline, pretomanid, and linezolid), have emerged as promising alternatives…
Budak M, Via LE, Weiner DM, Barry CE 3rd, Nanda P, et al.
…nization has focused goals of shortening standard treatment regimens for TB in their End TB Strategy efforts, which aim to reduce TB-related deaths by 95% by 2035. For this purpose, many novel and promising combination antibiotics are being explored that have recently been discov…
Nusrat Shafiq, Ashok Kumar, Vikram Vohra, Gopal Krishan Khuller, Manjula Singh, et al.
**BACKGROUND:** Clofazimine, an antimycobacterial agent, has demonstrated efficacy in reducing the treatment duration for MDR TB. **OBJECTIVES:** To determine whether a 16 week clofazimine-based regimen is non-inferior to the standard 24 week regimen for drug-susceptible pulmona…
Vibol Iem, Sakhone Suthepmany, Vongkham Inthavong, Anousone Sisouvanh, Khamloun Choumlivong, et al.
…is (MDR/RR-TB) was introduced under the TDR Short, all-Oral Regimens for Rifampicin-resistant Tuberculosis (ShORRT) initiative. **METHODS:** A retrospective and prospective comparative cohort study was conducted across five drug-resistant tuberculosis treatment centres from Janu…
Van Deun A, Decroo T, Kuaban C, Noeske J, Piubello A, et al.
…llected from patients starting one of the shorter treatment regimens (STRs) for multidrug-resistant tuberculosis (MDR-TB) in Bangladesh, Niger or Cameroon. OBJECTIVE: To estimate the effect of either a gatifloxacin (GFX), moxifloxacin (MFX) or levofloxacin (LVX) based STR on bact…
Malaisamy Muniyandi, Karikalan Nagarajan, Karthick Chelvanayagam, Kavitha Rajsekar, Kirti Tyagi, et al.
…s resistant to rifampicin (RR-TB) are limited and available regimens are often lengthy and poorly tolerated. However, following recent evidence from the TB PRACTECAL trial, countries are considering programmatic adoption of six-month, all-oral treatment regimen such as bedaquilin…
Rupani MP, Dave JD, Parmar VB, Singh MP, Parikh KD
…iscontinuation of multidrug-resistant tuberculosis (MDR-TB) regimens have not been studied in Gujarat. We aimed to find out the adverse drug reactions (ADRs) and predictors for discontinuation of MDR-TB regimens. Methods We conducted this cross-sectional study in Bhavnagar distri…
Rich ML, Khan U, Zeng C, LaHood A, Franke MF, et al.
…ness of the WHO-recommended design of longer individualized regimens for multidrug- or rifampicin-resistant TB (MDR/RR-TB) is limited. OBJECTIVES: To report end-of-treatment outcomes for MDR/RR-TB patients from a 2015-2018 multi-country cohort that received a regimen consistent w…
Preethi Koyyana, Mohana Pradeepika Machcha, Rajasekharam Gunta, Dhilleswara Rao Pudi
… reduction of social stigmatization. In contrast to earlier regimens that contained injectable drugs, the World Health Organization has recommended all-oral regimens for the treatment of Multidrug-Resistant/Rifampicin-Resistant-TB since 2018, which represents a significant advanc…
Jyoti Bajpai, Darshan Kumar Bajaj, Sandeep Kumar, Rashmi Kushwaha, Surya Kant, et al.
…fication test)&LPA(Line Probe Assay)and availability of regimens with duration of 9-11months in contrast to previous lengthy regimens things have become better. Present study was undertaken to study microbiological conversion and adverse effect profile of shorter regimen <b>M…
Muhammad Rifqy Alvy Widodo, Ida Srisurani Wiji Astuti, Inke Kusumastuti, Angga Mardro Raharjo, Supangat Supangat, et al.
… comparison between the administration of individual MDR-TB regimens and short-term regimens concerning anxiety levels in MDR-TB patients at Dr. Soebandi Regional General Hospital, Jember. Methods: This was an analytical observational study with a cross-sectional design. It was c…
Avaliani T, Sereda Y, Davtyan H, Tukvadze N, Togonidze T, et al.
Tuberculosis treatment is challenging, especially among people with drug-resistant forms of tuberculosis. The introduction of fully oral modified short treatment regimen has a great potential to shorten duration of treatment, improve safety and ultimately increase treatment succe…
Ginenus Fekadu, Tadesse Tolossa, Firomsa Bekele, Xiaohan Chen, Yan He, et al.
…line (Bdq), has led to the development of shorter treatment regimens. This systematic review and meta-analysis aimed to examine the impact of these regimens, synthesising data from recent clinical trials and observational studies. **METHODS:** We searched multiple databases, inc…
Phillips PPJ, Van Deun A, Ahmed S, Goodall RL, Meredith SK, et al.
…to 84.2% across five alternative outcomes. However, between-regimens results did not exceed 1.3% in favor of the long regimen (95% CI upper bound 10.1%), similar to the primary efficacy results from the trial. Considering only Definite or Probable FoR events, there was weak evide…
Mojisola Clara Hosu, Lindiwe Modest Faye, Teke Apalata
…time ranged from 29 to 59 days. Patients on short treatment regimens converted significantly faster than those on long regimens (= 7.55 × 10), with 90% of short-regimen patients achieving favorable outcomes compared to 52% in the long regimen group (= 0.0000040). Spearman co…
Ur Rehman O, Fatima E, Ali A, Akram U, Nashwan A, et al.
…ire treatment with newer drugs. Bedaquiline based treatment regimens have been used in patients who are diagnosed with drug resistant tuberculosis. The aim of this study is to assess the efficacy and safety profile of bedaquiline-based treatment regimens using a systematic review…
Feng Sun, Yang Li, Yilin Zhang, Cui Cai, Yuanyuan Chen, et al.
**OBJECTIVES:** Despite advancements in shorter, oral regimens for drug-resistant tuberculosis, more options are needed to extent patient benefits. We conducted a trial to evaluate the noninferiority of an all-oral regimen compared with the injectable-containing regimen. **METHO…
Trébucq A, Decroo T, Van Deun A, Piubello A, Chiang CY, et al.
…ug-resistant tuberculosis (MDR-TB) treatment. Similar short regimens were studied in different settings, relying for their efficacy on a later generation fluoroquinolone, either gatifloxacin, moxifloxacin, or levofloxacin. We review the published material on short MDR-TB regimens…
Bada FO, Blok N, Okpokoro E, Dutt S, Akolo C, et al.
…d treatment success rates of 52-66% while shorter treatment regimens have reported success rates of 85% and above. In addition, replacing the second-line injectable agent in a shorter treatment regimen with bedaquiline has been found to further improve treatment success in patien…
Ardhianto D, Suharjono, Soedarsono, Fatmawati U
…ion. The aim was to study the differences in the use of BDQ regimens to the lengthening of the QTc interval and to study risk factors (diabetes, hypokalemia, sex, BMI, and age) in BDQ regimen. Methods This study was an observational retrospective study with a total sampling metho…
Van Deun A, Decroo T, Kya Jai Maug A, Hossain MA, Gumusboga M, et al.
…two months), but had little impact on rifampicin-throughout regimens: (6 months, new cases; 3.8%; OR 0.8, 95%CI:0.3,2.8; 8 months, retreatment cases: 7.3%, OR 1.8; 95%CI:1.3,2.6). Rr was missed in 7.6% of randomly selected "Hr" strains. Acquired Rr was frequent among recurrences …